loading page

COVID-19 and Mucormycosis: The Double Edge Sword
  • +3
  • Siddheesh Rajpurohit,
  • Annam Prathiba,
  • Kangan Ghadiali,
  • Kanav Khera,
  • Sheetal Chauhan,
  • Ajit Singh
Siddheesh Rajpurohit
Manipal College of Pharmaceutical Sciences

Corresponding Author:[email protected]

Author Profile
Annam Prathiba
Author Profile
Kangan Ghadiali
Author Profile
Kanav Khera
Manipal Academy of Higher Education
Author Profile
Sheetal Chauhan
Author Profile
Ajit Singh
Kasturba Medical College Manipal
Author Profile


Background and aim India has declared mucormycosis as an epidemic. The incidence rate is rising day by day as there are more than 29000 cases in 28 states until March 2021. COVID-19 is already burdening the health care system, and post-COVID mucormycosis leads to mortality and morbidity in patients treated with COVID-19. This article aims to understand the various complications of mucormycosis and how it is impacting COVID-19 infected patients. Methods A thorough literature search was performed using PubMed, Google Scholar, and Embase from May 2021 to June 2021. The authors selected the articles based on relevance. Mucormycosis, black fungus, fungal infection, COVID-19, pathogenesis, corticosteroids, treatment, antifungals were the major keywords searched. Secondary resources included from the published news articles. Results Through the literature, we observed that patients after COVID-19 are more vulnerable to these fungal infections, especially immunocompromised patients, patients with long-term steroid use, and uncontrolled diabetes. This review enlightens the manifestations, pathogenesis, and various treatment and anticipation policies for mucormycosis. Conclusion Awareness about the possibility of the disease is necessary to reduce the delay of diagnosis and timely treatment to prevent further implications of the disease. In addition, prevention of the disease with strict follow-up measures with sanitation and hygiene maintenance is also essential.